Insurers also point to inconsistent use of the medications
Horwitz, R
KEY TAKEAWAYS: Rising global burden of obesity, diabetes, hypertension, and cardiovascular diseases is accelerating demand for advanced cardiometabolic therapies Growing adoption of GLP-1 receptor agonists and SGLT2 inhibitors is transforming chronic disease management Increasing focus on integrated cardio-renal-metabolic care is improving patient outcomes and expanding therapeutic applications Advances in RNA-based therapeutics, gene-editing technologies, and precision medicine are creating new treatment opportunities Strong clinical pipelines targeting obesity, metabolic liver disease (MASH), lipid disorders, and heart failure are driving market expansion Strategic partnerships between pharmaceutical and biotechnology companies are accelerating drug development and commercialization North America leads the market due to advanced healthcare infrastructure, favorable reimbursement systems, and early adoption of innovative therapies, while Asia-Pacific is emerging as a high-growth region
If the products are independently third-party tested, the supplements are unlikely to be harmful if theyre taken in reasonable doses, White notes
Even as prices come down for GLP-1 weight-loss drugs, much cheaper products marketed as GLP-1 supplements can be alluring to consumers
If you have concerns, please contact our healthcare team or your primary care physician
